Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
13(45%)
Results Posted
60%(3 trials)
Terminated
3(10%)

Phase Distribution

Ph phase_1
4
14%
Ph phase_3
4
14%
Ph phase_2
16
55%
Ph not_applicable
3
10%

Phase Distribution

4

Early Stage

16

Mid Stage

4

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
4(14.8%)
Phase 2Efficacy & side effects
16(59.3%)
Phase 3Large-scale testing
4(14.8%)
N/ANon-phased studies
3(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

13

trials recruiting

Total Trials

29

all time

Status Distribution
Active(14)
Completed(5)
Terminated(3)
Other(7)

Detailed Status

unknown7
Recruiting7
Active, not recruiting6
Completed5
Terminated3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
13
Success Rate
62.5%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (14.8%)
Phase 216 (59.3%)
Phase 34 (14.8%)
N/A3 (11.1%)

Trials by Status

active_not_recruiting621%
not_yet_recruiting13%
unknown724%
completed517%
recruiting724%
terminated310%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT06536868Phase 2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Recruiting
NCT07538271Phase 2

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

Not Yet Recruiting
NCT03923270Phase 1

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active Not Recruiting
NCT05223647Phase 3

Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer

Terminated
NCT05353257Phase 3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active Not Recruiting
NCT04472949Phase 2

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Active Not Recruiting
NCT05796089Phase 2

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Active Not Recruiting
NCT04380636Phase 3

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Active Not Recruiting
NCT05298423Phase 3

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Active Not Recruiting
NCT00328562Phase 1

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Completed
NCT06869239

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Recruiting
NCT06771518Phase 2

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Recruiting
NCT05552846Not Applicable

Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy

Recruiting
NCT06586697Phase 2

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Recruiting
NCT06354530Phase 2

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting
NCT06187740Phase 1

Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy

Unknown
NCT05651802Not Applicable

PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients

Recruiting
NCT03673657Phase 2

Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer

Completed
NCT03663166Phase 1

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Terminated
NCT04863027

Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.

Completed

Drug Details

Intervention Type
RADIATION
Total Trials
29